期刊
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
卷 12, 期 2, 页码 119-125出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-017-0373-2
关键词
Chimeric antigen receptor; Multiple myeloma; B cell maturation antigen; Adoptive T cell therapy; Clinical trials
资金
- The Danish Cancer Society [R153-A9829] Funding Source: researchfish
- NCI NIH HHS [K08 CA166039] Funding Source: Medline
The recent clinical success of CD19-directed chimeric antigen receptor (CAR) T cell therapy in chronic and acute leukemia has led to increased interest in broadening this technology to other hematological malignancies and solid tumors. Now, advances are being made using CAR T cell technology to target myeloma antigens such as B cell maturation antigen (BCMA), CD138, and kappa-light chain as well as CD19 on putative myeloma stem cells. To date, only a limited number of multiple myeloma patients have received CAR T cell therapy but preliminary results have been encouraging. In this review, we summarize the recently reported results of clinical trials conducted utilizing CAR T cell therapy in multiple myeloma (MM).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据